Biofrontera Inc. Reports Q3 2025 Results and Strategic Moves

Biofrontera, Inc. ( (BFRI) ) has released its Q3 earnings. Here is a breakdown of the information Biofrontera, Inc. presented to its investors.

Biofrontera Inc. is a biopharmaceutical company focused on developing and commercializing photodynamic therapy (PDT) for dermatological conditions, particularly actinic keratoses, a pre-cancerous skin lesion. The company is based in the United States and is listed on NASDAQ under the ticker BFRI.

In its third-quarter 2025 earnings report, Biofrontera Inc. announced stable revenues for the first nine months of the year, despite a decline in third-quarter revenues due to advanced purchases in the previous year. The company highlighted strategic moves, including the acquisition of U.S. assets from Biofrontera AG and the divestiture of its Xepi antibiotic cream.

Key financial metrics showed a slight decline in revenues to $7.0 million in Q3 2025 from $9.0 million in Q3 2024, attributed to the prior year’s advanced purchases. Operating expenses decreased by 5% year-over-year, and the company reported a net loss of $6.6 million for the quarter. Notably, Biofrontera completed a significant acquisition of Ameluz and RhodoLED assets, which is expected to enhance gross margins and long-term profitability.

The company is optimistic about its future, with expectations of substantial revenue growth in the fourth quarter and beyond. Biofrontera’s management remains confident in achieving full-year sales objectives, supported by the growing demand for its Ameluz-PDT treatment and strategic operational changes.

Looking ahead, Biofrontera Inc. is focused on expanding the use of its Ameluz product for additional indications and improving its financial leverage through strategic acquisitions and partnerships. The company’s management is committed to sustaining growth and profitability in the coming quarters.